ANNOUNCEMENTS

ACUTE LEUKEMIA SYMPOSIUM
April 12-13, 1984
Detroit, Michigan

17TH ANNUAL CANCER SYMPOSIUM

Presented by: Wayne State University School of Medicine, Division of Oncology, Comprehensive Cancer Center of Metropolitan Detroit, and Harper-Grace Hospitals

April 12, 1984
9:00 a.m. The Impact of Treatment of the Natural History of Acute Leukemia, Emil Freireich
9:45 a.m. Monoclonal Antibody Classification of Leukemia and Lymphoma: Implications for Normal Leukocyte and Differentiation, Kenneth Palutke
10:30 a.m. The Laboratory Diagnosis of Leukemia: Morphology, Cytochemistry, Cell Surface Markers, and DNA Analysis, Margarita Palutke
11:00 a.m. COFFEE BREAK
11:30 a.m. Transfusion Therapy for the Support of Leukemia Patients, Chatchada Karanes
12:00 p.m. Leukemia: Hemorrhagic and Thrombotic Complications, John Penner
12:30 p.m. LUNCH
2:00 p.m. Experimental Rationale for Therapy in the Treatment of Acute Leukemia, Frederick Valeriote
2:45 p.m. Evolution of Therapy for Childhood Acute Leukemia, Teresa Vietti
3:30 p.m. COFFEE BREAK
4:00 p.m. Chemotherapeutic Agents as Differentiation Inducers, Alexander Block
4:30 p.m. Present Protocols for Treatment of Childhood Leukemia, Y. Ravindranath

April 13, 1984
6:00 p.m. Cocktails at the Detroit Institutes of Art
7:00 p.m. Supper at the Detroit Institutes of Art
9:00 a.m. T Cell Lymphodines and HTLV, David Golde
9:45 a.m. Oncogene Arrangement and Expression in Leukemia, Steven Collins
10:15 a.m. COFFEE BREAK
10:30 a.m. Clonal Variation and Phenotypic Progression in Retrovirus Transformed Leukemia Cells, David Hines
11:00 a.m. Uses of Biological Response Modifiers in the Treatment of Leukemia and Lymphoma, Kenneth Foon
11:30 a.m. LUNCH
1:30 p.m. Transplantations versus Chemotherapy; Predictions of Response, Harvey Preisler
2:15 p.m. Transplantation in Acute Leukemia?, Frederick Applebaum
3:00 p.m. COFFEE BREAK
3:30 p.m. Overview of Treatment of Acute Non-Lymphocytic Leukemia in Adults, Michael Rooney
4:00 p.m. Determinants in Indices of Drug Responsiveness in Acute Leukemias, David Kessel
4:30 p.m. SUMMARY, Laurence Baker
4:45 p.m. ADJOURN

Guest Faculty: F. Applebaum, Seattle; A. Block, Buffalo; S. Collins, Seattle; K. Foon, Frederick; E. Freireich, Houston; D. Golde, Los Angeles; D. Hines, Detroit; J. Penner, East Lansing; H. Preisler, Buffalo; T. Vietti, St. Louis

Wayne State University Faculty: L. Baker; C. Karanes; D. Keesel; M. Palutke; Y. Ravindranath; M. Rooney; F. Valeriote

For information about the content, contact Dr. L. Baker, Wayne State University, Division of Oncology, P.O. Box 02188, Detroit, MI. Telephone: (313) 494-4700.

To receive brochure or to register, contact Mrs. Anita Harper, Division of C.M.E., 4-H University Health Center, 4201 St. Antoine, Detroit, MI 48201. Telephone: (313) 577-1180.
WORLD HEALTH ORGANIZATION

The World Health Organization is supporting an International Registry for Prenatal Monitoring of Hereditary Anemias. This includes cases studied by fetal blood, amniocentesis, or chorionic villi, and ranges from hemoglobinopathies to white cell disorders to nonhematologic diseases studied by fetal blood. Please contact Blanche P. Alter, M.D., Polly Annenberg Levee Hematology Center, Mount Sinai School of Medicine, One Gustave Levy Place, New York, NY 10029 to obtain Registry forms and further information.

ADVANCES IN CANCER RESEARCH
March 16–17, 1984

The Albert Einstein Cancer Center (Albert Einstein College of Medicine/Montefiore Medical Center) announces the First Annual Symposium directed by Peter Wiernik, M.D., taking place in New York City. Topics will include both clinical and laboratory advances in the study and treatment of neoplastic disease. AMA Category I credit. For information and brochure contact Einstein’s Office Of CME, 111 E. 210th Street, Bronx, NY 10467. Telephone: (212) 920-6674.

EIGHTEENTH ANNUAL CLINICAL SYMPOSIUM

St. Jude Children’s Research Hospital, Memphis, Tennessee, will hold its Eighteenth Annual Clinical Symposium on February 24–25, 1984. The symposium will be open to all physicians who wish to attend.

The symposium will be concerned with current results in the treatment of children with cancer and leukemia. Emphasis will be given to diagnosis and treatment programs for primary disease as well as to the care of complications. There will be discussions of various aspects of supportive care as an essential adjunct to chemotherapy regimens.

Approximately 200 physicians will be accepted for participation in the symposium on a first come basis. There are no registration or other fees. Physicians can register by writing to: Director, St. Jude Children’s Research Hospital, Box 318, Memphis, TN 38101. Early registration is advised.

HAEMONETICS RESEARCH INSTITUTE
11TH INTERNATIONAL ADVANCED APHERESIS SEMINAR

Hyatt Regency, Cambridge
Boston, MA USA
April 30–May 1, 1984

For information, contact Janet L. Cumming, Haemonetics Research Institute, 400 Wood Road, Braintree, MA 02184. Telephone: (617) 848-7100 or Telex No. 921 817 Haemonetic Brae.
COOLEY'S ANEMIA FOUNDATION, INCORPORATED

Research Grants and Fellowships

The Cooley's Anemia Foundation, Incorporated, invites applications for research grants up to $25,000 and for fellowships with stipends up to $15,000 in the field of Cooley's anemia. The deadline for receipt of applications is April 1, 1984. Awards will be made by June 15, 1984, and funding will begin July 1, 1984 for one year with the possibility of renewal for a second year.

For application forms and further information, contact:

Mr. Michael DiFilippo
Executive Director
Cooley's Anemia Foundation, Incorporated
105 East 22nd Street
Suite 911
New York, NY 10010
Telephone: (212) 598-0911

6TH INTERNATIONAL SYMPOSIUM ON PREVENTION AND DETECTION OF CANCER

November 26–29, 1984
Vienna, Austria

Sponsored by the International Society for Preventive Oncology, World Health Organization, Austrian Cancer Society–Austrian Cancer League, and Association of Clinical Scientists–USA.

The program includes overview lectures, panels, poster sessions, scientific exhibits, and special workshops designed for critical appraisal of current data. Discussions are to concentrate on actions to be taken, and on the implementation of existing knowledge for effective cancer control by primary and secondary prevention. Reports are to present progress in multifactorial etiology of oncogenesis, molecular biology, identification of high risk groups, tumor susceptibility, and clinical and laboratory manifestations of cancer, including tumor markers. Participants include the clinician, epidemiologist, pathologist, experimental oncologist, immunologist, socioeconomist, educator, and members of the health care team.

Abstracts of presentations are invited by June 15, 1984. Abstracts and program appear in Cancer Detection & Prevention 1984:7(6). Award(s) for outstanding investigation(s) presented by ISPO. The symposium is accredited for 32 CME credit hours. Contact: the International Society for Preventive Oncology, 207 East 85th St., Suite 303, New York, NY 10028, USA. Telephone: 212-534-4991; toll-free in USA, 1(800)527-0297; outside Europe, (USA-214)392-3663; in Europe, (AUSTRIA 43-222)52-0544.
Factor Deficient Human Plasma

- Substrate Quality
- Stable
- Fresh Frozen
- Mono-Specific

(Partial) Price List (F.O.B. Overland Park, Kansas)

<table>
<thead>
<tr>
<th>Coagulation Deficiency</th>
<th>In Vials</th>
<th>In Bags</th>
</tr>
</thead>
<tbody>
<tr>
<td>Factor XI, XII</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 ml</td>
<td>$60.00</td>
<td>250 ml</td>
</tr>
<tr>
<td>25 ml</td>
<td>145.00</td>
<td>500 ml</td>
</tr>
<tr>
<td>50 ml</td>
<td>280.00</td>
<td>1000 ml</td>
</tr>
<tr>
<td>100 ml</td>
<td>540.00</td>
<td></td>
</tr>
<tr>
<td>Factor VIII</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 ml</td>
<td>$32.50</td>
<td>250 ml</td>
</tr>
<tr>
<td>25 ml</td>
<td>75.00</td>
<td>500 ml</td>
</tr>
<tr>
<td>50 ml</td>
<td>137.50</td>
<td>1000 ml</td>
</tr>
<tr>
<td>100 ml</td>
<td>250.00</td>
<td></td>
</tr>
</tbody>
</table>

- All shipments are packed with dry ice in styrofoam boxes. (Handling Charge for orders under $250.00).
- Shipments within the United States are usually delivered within 24 hours.
- Plasma can be aliquoted in any amount up to 5 ml at an additional charge of $0.50 per vial.
- Special discount prices upon request for standing orders or large volumes.

Also available — • FACTORS I, II, V, VII, IX, X, XIII • FACTORS VIII or IX with inhibitor

Prekallikrein Deficient • Von Willebrand Trait • Passovoy Trait • Kininogen Deficient

Normal Reference Human Plasma

For Complete Details — Write or Call

GEORGE KING BIO-MEDICAL, INC.,
9209 West 110 Street, Overland Park, KS 66210

Toll free 1-800-255-5108 Phone (913) 649-2272

---

Harcourt Brace Jovanovich, Inc.
Dept. Computer SAT 1250 6th Avenue
San Diego, CA 92101

Please send me ______ Computer GRE

$7995

Quantity

for my Apple II or Apple II Plus or Apple IIe

Please send me ______ Computer SAT

$8995

Quantity

for my Apple II or Apple II Plus or Apple IIe or IBM PC

Please send more information

FOR CREDIT CARD ORDERS CALL TOLL-FREE
800-543-1918 (in California call collect 619) 699-6335

Act # ___________ Exp ___________

Signature ___________________ Name ___________________

Address _____________________ City ___________ State ___________ Zip ________

Method of Payment: Check ___________ Money Order ___________

Charge My Visa MasterCard American Express

The Alan Computer SAT
PC 563
New titles from Academic Press in cancer research and related sciences.

INTERFERONS
UCLA Symposia on Molecular and Cellular Biology, Volume XXI, 1982
Edited by THOMAS C. MERIGAN and ROBERT M. FRIEDMAN
This volume contains the proceedings of a major international conference on the Chemistry and Biology of Interferons: Relationships to Therapeutics, held in March 1982. The topics discussed include 1) the recombinant DNA production of interferon, 2) the biology of interferons, 3) factors relevant to the clinical application of interferons, and 4) clinical studies of interferon. This volume also includes papers from the forty-four speakers at the nine plenary sessions and abstracts from the workshop participants.
1982, 481 pp., $42.00 ISBN: 0-12-491220-6

CHEMICAL INDUCTION OF CANCER
STRUCTURAL BASES AND BIOLOGICAL MECHANISMS
JOSEPH C. ARCOS, YIN-TAK WOO, and MARY E. ARGUS; with the collaboration of DAVID Y. LAI
Volume 3A/ALIPHATIC CARCINOGENS
Focusing on the relationship between chemical structure and carcinogenicity, this volume presents extensive discussions of the metabolic aspects and mechanisms of carcinogenic action: physiochemical properties; mutagenicity and teratogenicity; modification of carcinogenicity by endogenous or exogenous factors; environmental formation and occurrence; and potential human exposure.
Volume 3A: 1982, 752 pp., $78.00 ISBN: 0-12-059303-3

THE CELL NUCLEUS
Volume X: rDNA, Part A
Volume XI: rDNA, Part B
Volume XII: rDNA, Part C
Edited by HARRIS BUSCH and LAWRENCE ROTHBLUM
Since the publication of "The Nucleolus" in 1970, tremendous advances have been made on the description, sequences, and analysis of controls of the gene coding for ribosomal RNA and ribosomal proteins. These three volumes review this remarkable progress as of 1982 and point to the areas for future research.
Volume X first discusses the ribosomal RNA genes of Escherichia coli, algae, fungi, Dictyostelium and Physarum, and the protozoans. The expert contributors also deal with special features of the rRNA product of Tetrahymena and review the rDNA of higher organisms, including sea urchins, insects, and humans. Later chapters present recent developments in structural analysis of 18 S rRNA and rDNA, the evolutionary patterns of 28 S rDNA, and the mitochondrial rDNA. Volumes XI and XII cover the 5 S rDNA, nucleolar, and other rDNA-containing chromatin as visualized by light and electron microscopy, and the organization of rDNA in chromatin. These volumes also present the important subjects of transcription and transcriptional control of the rDNA genes, the amplification of rDNA, and the controls of ribosomal genes.
Volume X: 1982, 448 pp., $65.00 ISBN: 0-12-147610-3
Volume XI: 1982, 328 pp., $45.00 ISBN: 0-12-147611-1
Volume XII: 1982, 280 pp., $42.00 ISBN: 0-12-147612-x

TERATOCARCINOMA AND EMBRYONIC CELL INTERACTIONS
Edited by TAKASHI MURAMATSU, GABRIEL GACHELIN, A. A. MOSCONA, and YOJI IKAWA
This monograph consists largely of papers presented at the First Hiei International Symposium on Teratocarcinoma and the Cell Surface held in Kyoto, Japan in October 1980. Editorial notes covering other aspects of the application of the teratocarcinoma cell system have been included, so that the volume can serve as a summary of current knowledge from both the biological and molecular viewpoints.
1982, 311 pp., illus., $81.00 ISBN: 0-12-511180-0

TUMOR CELL HETEROGENEITY
ORIGINS AND IMPLICATIONS
Edited by ALBERT H. OWENS, JR., DONALD S. COFFEY, and STEPHEN B. BAYLIN
A Volume in the BRISTOL-MYERS CANCER SYMPOSIUM Series
Based on the proceedings of the Fourth Annual Bristol-Myers Symposium on Cancer Research, held at the Johns Hopkins Oncology Center in December 1981, this volume presents the latest research on the genetic and epigenetic mechanisms involved in tumor cell heterogeneity. It emphasizes the implications of these mechanisms for the pathogenesis of neoplastic disorders and their practical clinical management. The contributions by leading authorities from different sectors of the cancer research community provide essential reading for those seeking a complete understanding of neoplasia.
1982, 520 pp., $199.50 ISBN: 0-12-531520-1

CELL SEPARATION
METHODS AND SELECTED APPLICATIONS
VOLUME 1
Edited by THOMAS G. PRETLOW II and THERESA P. PRETLOW
This authoritative treatise presents current methods for obtaining highly purified, viable cells. Several techniques for separating a broad range of cells are covered, including cells from cancer, the gastrointestinal tract, lymphoid tissues, marrow, and the pituitary. Emphasizing the practical aspects of cell separation, this volume is directed toward a heterogeneous audience: experimental oncologists, hematologists, cell biologists, endocrinologists, and others who want to increase their understanding of the use of methods for cell separation.
1982, 352 pp., $35.00 ISBN: 0-12-564501-5

B AND T CELL TUMORS:
BIOLOGICAL AND CLINICAL ASPECTS
UCLA Symposia on Molecular and Cellular Biology, Volume XXIV, 1982
Edited by ELLEN S. VITTELA
This international conference, brought together 400 researchers studying tumor biology and clinical oncology as applied to lymphoid cells. This volume documents the proceedings in which scientists and clinicians discussed questions related to the origin and classification of tumors, normal clones of T and B cell tumors, differentiation of T and B cell tumors, regulation of tumor growth, and tumor therapy. The articles demonstrate the enormous advances that have been made in applying the new technologies of monoclonal antibodies, cell cloning/long-term culture, and genetic analysis of lymphoid tumors.
1982, 583 pp., $52.00 ISBN: 0-12-722380-0

Send payment with order and save postage and handling. Prices are in U.S. dollars and are subject to change without notice.

ACADEMIC PRESS, INC.
A Subsidiary of Harcourt Brace Jovanovich, Publishers
New York • London • Toronto • Sydney • San Francisco
111 FIFTH AVENUE, NEW YORK, N.Y. 10003
24-28 Oval Road, London NW1 7DX, England
313302 A
An important reference tool for the practicing oncologist...

SEMINARS IN ONCOLOGY

JOHN W. YARBRO, M.D., Ph.D.,
Editor-in-Chief
RICHARD S. BORNSTEIN, M.D. and MICHAEL MASTRANGELO, M.D.
Associate Editors

Seminars in Oncology provides the oncologist with a thorough review of important topics in the field. Each issue is devoted to an area of particular importance in which invited experts discuss a wealth of clinical experience. All practicing oncologists will find Seminars to be an outstanding source of current and reliable information.

TOPICS TO BE COVERED IN VOLUME 11 (1984):
March—AIDS
June—ESOPHAGEAL CANCER
September—HAIRY CELL LEUKEMIA
December—OVARIAN CANCER

Volume 11, 1984, published quarterly
ISSN: 0093-7754

Annual subscription rates, U.S.A. and Canada: $54.00 individuals/
$62.00 institutions and libraries
Outside U.S.A. and Canada: $63.00 individuals/$72.00 institutions and libraries

Journal subscriptions are for the calendar year and are payable in advance. Price includes postage, handling, and air freight where applicable. Prices are in U.S. dollars and are subject to change without notice.

Individuals may request information regarding personal subscription rates. Please direct all orders and inquiries to the Journal Subscription Fulfillment Department.

G&S
GRUNE & STRATTON
A Subsidiary of Harcourt Brace Jovanovich, Publishers
New York • London • Toronto • Sydney • San Francisco • San Diego • Orlando • Tokyo
111 FIFTH AVENUE, NEW YORK, NY 10003
A new, thoroughly revised, dramatically expanded edition of a classic in its field! A readable, comprehensive survey of all new developments!

LEUKEMIA 4th Edition

Edited by
FREDERICK W. GUNZ, M.D.
Formerly Kanematsu Memorial Institute, Sydney

EDWARD S. HENDERSON, M.D.
Roswell Park Memorial Institute
State University of New York at Buffalo

All previous editions of this work have been acclaimed. The third edition, published in 1974, was characterized as “authoritative” by D. P. Shreiner in the Journal of the American Medical Association and “a classic in the field of hematology” by William C. Moloney in Blood. This new 4th edition expands upon that tradition of excellence. For the first time, the work is multi-authored, with contributions from twenty-six clinical and laboratory experts from the United States, Australia, the United Kingdom and France. They provide important, up-to-date material on all aspects of human leukemia, including clinical and pathological aspects, etiology, incidence, and prognosis. This new edition is an indispensable sourcebook for all specialists and practicing physicians in hematology, oncology, pediatrics, and pathology.

CONTENTS:

INTRODUCTION
Frederick W. Gunz, Leukemia in the Past
Edward S. Henderson, Definition and Classification
Fredrick W. Gunz, Epidemiology

THE NATURE OF LEUKEMIA
Paul C. Vincent, Pathophysiology
Philip J. Fialkow, Clonal Development and Stem Cell Origin of Leukemias and Related Disorders
Paul C. Vincent, Kinetics of Leukemia and Control of Cell Division and Replication
Jun Minowada, Immunology of Leukemic Cells
John F. Smyth, Biochemistry of Leukemic Cells
J. Breton-Gorius, Ultrastructure of Leukemic Cells
O. Margarete Galson, Cytogenetics of Leukemic Cells
Edward S. Henderson, Pathology of the Leukemic Tissue
Paul C. Vincent, Special Clinical and Laboratory Manifestations

ETIOLOGY OF LEUKEMIA
Edward S. Henderson, Etiology of Leukemia: A Persistent Puzzle
Henry S. Kaplan, Animal Models of Leukemia and Lymphoma
Fredrick W. Gunz, Genetic Factors in Human Leukemia
Flossie Wong-Staal and Robert C. Gallo, Retroviruses and Leukemia
Fredrick W. Gunz, Ionizing Radiation and Human Leukemia
Fred Rosner and Hans H. Grünwald, Chemicals and Leukemia

DIAGNOSIS OF LEUKEMIA
Edward S. Henderson, Clinical Diagnosis
John M. Bennett, Leukemia Morphology and Cytochemistry

GENERAL CONSIDERATIONS OF TREATMENT
Edward S. Henderson, Terminology and Perspectives
Patrick J. Creaven and Toucet M. Rustum, Principles of Chemotherapy: Drug and Biochemical Determinants

Send payment with order and save postage and handling. Prices are in U.S. dollars and are subject to change without notice.

Grune & Stratton
A Subsidiary of Harcourt Brace Jovanovich, Publishers
New York • London • Toronto • Sydney • San Francisco
111 FIFTH AVENUE, NEW YORK, N.Y. 10003

1983. 1024 pp., 204 illus. including 30 in color, $109.00

353004
THE DIVISION OF HEMATOLOGY, STANFORD UNIVERSITY SCHOOL OF MEDICINE invites applications for the Director of a newly established Bone Marrow Transplantation Program at the rank of Assistant or Associate Professor of Medicine. If the candidate is exceptionally well qualified the rank of Professor (which automatically confers tenure) could be considered. Candidates should have evidence of ongoing investigative programs in relevant research areas, and should, in addition, be skilled in clinical aspects of marrow transplantation. Applicants should send a curriculum vitae, a brief statement of their research interests and the names of two referees to: Stanley L. Schrier, M.D., Chief, Division of Hematology, Stanford University School of Medicine, Stanford, CA. 94305. Stanford University is an equal opportunity employer and welcomes nominations of women and minority group members and applications from them.

Associate Director TRANSFUSION SERVICE

Major university teaching hospital in New York City is seeking a physician, Board-certified in Internal Medicine, and qualified for Blood Bank Director's licensure in New York City. Position available immediately. Excellent salary and fringe benefits. Send resume to John F. Bertles, MD, Chief, Hematology-Oncology.

St. Luke's-Roosevelt Hospital Center
114th Street & Amsterdam Ave
New York, NY 10025
an equal opportunity employer

INDEX TO ADVERTISERS
FEBRUARY 1984

JANSSEN PHARMACEUTICA
Nizoral .................................................. ix, x
MEAD JOHNSON
Cytospan .............................................. xxiv, xxv, xxvi
ORTHO DIAGNOSTIC SYSTEMS, INC.
Hematology Product Line ........................ xi
SANDOZ, INC.
Sandimmune ........................................ xix, xx, xxi, xxi
SHERWOOD MEDICAL
Monoject (needles & syringes) ..................... 2C, iii
SPRINGER-VERLAG, PUBLISHERS .............. xxvii
WELLCOME DIAGNOSTICS A DIVISION OF THE
BURROUGHS WELLCOME COMPANY
Thrombo-Wellcotest ............................... xxxvii

CLASSIFIED ADS
ST. LUKES-ROOSEVELT HOSPITAL CENTER
Associate Director Transfusion Service ........ xliii
STANFORD UNIVERSITY
Director Bone Marrow Transplantation Program .... xliii

ACADEMIC PRESS, PUBLISHERS ................................ xl
AMERICAN SCIENTIFIC PRODUCTS ............ Synerex—CC180 4C
BIO/DATA CORPORATION ......................... iv
BURROUGHS WELLCOME COMPANY ......... Wellcovin xvi, xxiv, xxix
Zovirax .................................................... xii, xiii, xiv
CHRONO-LOG CORPORATION The Whole Blood Aggregometer xv
CUTTER BIOLOGICAL
Gammut ............................................. xxx, xxxi, xxxii
Nutreol .................................................. xxxiv
GENZYM CORPORATION
Lymphokines ........................................ 3C
GEORGE KING BIO-MEDICAL, INC.
Factor Deficient Human Plasma ............... xxxix
GRUNE & STRATTON, PUBLISHERS ......... xxiii, xxxi, xli, xlii, xliii
HARCOURT BRACE JOVANOVICH, PUBLISHERS ........ xxiv, xxv, xxvi
HYCLONE sterile (systems, inc.) .................... xxiv
Ivies LABORATORIES
Cerulidine .......................................... xvi, xvii

INDEX TO ADVERTISERS
FEBRUARY 1984
A practical clinical guide to diagnosis, treatment, and prevention...

THE CLINICAL APPROACH TO THALASSAEMIA

BERNADETTE MODELL
Department of Obstetrics and Gynaecology
Faculty of Clinical Sciences
University College, London

VASILI BERDOUKAS
Department of Paediatrics
Prince of Wales Children’s Hospital
Sydney, Australia

The most up-to-date methods of preventing and treating thalassaemia major, the most common of all lethal inherited conditions, are clearly and practically presented here. Methods of preventing this hitherto fatal childhood anaemia, including population screening, genetic counselling, and fetal diagnosis, are described in detail. The authors examine the effective management of the disease through blood transfusion and iron chelation therapy and provide information on the genetics, biochemistry, pathophysiology, and the social and psychological implications of the disease. Clinicians concerned with the treatment and prevention of thalassaemia—paediatricians, haematologists, geneticists, obstetricians, and community physicians—will find this work to be filled with invaluable, practical suggestions to aid them in the management and eradication of the disease.

CONTENTS (Section Headings)

December 1983, 464 pp., $49.00

Send payment with order and save postage and handling.
Prices are in U. S. dollars and are subject to change without notice.

GRUNE & STRATTON
A Subsidiary of Harcourt Brace Jovanovich, Publishers
New York • London • Toronto • Sydney • San Francisco • San Diego • Orlando • Tokyo
111 FIFTH AVENUE, NEW YORK, NY 10003
Highly Purified

LYMPHOKINES

For Biological Research

Immunological advances begin here

A new line of lymphokines has been produced for the research community at Genzyme laboratories in Boston and England. These products, the first in a series, have been developed in collaboration with Immunex Corporation under the technical direction of noted immunologists Steven Gillis and Christopher Henney.

Ultrapure Interleukin 1 (Human)

The first and only commercially available source of this lymphokine, Genzyme Ultrapure Interleukin 1 is derived from glass adhered human monocytes, purified by antibody affinity chromatography and gel filtration. This preparation is free of other growth factors and inducer substances. Its activities include the enhancement of in vitro proliferation response of T-cells to T-cell mitogens as well as increasing the plaque forming response of mouse spleen cells and increasing in vitro antibody formation from B-cells.

Ultrapure Interleukin 2 (Human)

This cell-lined derived preparation of Interleukin 2 is free of Interleukin 1, Colony Stimulating Factor, Interferon, Macrophage Activating Factor, and inducer substances. It is supplied at a titre of 5000 units per ml and has a specific activity of 70 u/g. This lymphokine is suitable for long-term culture of T-cells.

Colony Stimulating Factor (Human)

This partially purified factor promotes differentiation and Colony formation in soft agar of undifferentiated human bone marrow cells. Both Granulocytes and Macrophages develop indicating that this preparation is a Type-II CSF. In addition, this factor will cause proliferation, but not colony formation, in murine bone marrow cells.

Colony Stimulating Factor (Mouse)

Like the human CSF, this preparation causes proliferation of murine bone marrow cells, colony formation in murine bone marrow cells, and in addition, supports the growth of FDCP-2 cells which have been shown to be Type-II CSF dependent.

Other products for biological research

Genzyme also offers a highly purified Nerve Growth Factor (Mouse). This 7S-NGF has been shown to be essential for the in vitro survival and growth of sympathetic and embryonic nerve cells. In addition, we offer purified Collagen-2 (Chicken) for induction of experimental arthritis in rats.

For laboratory use only. Not for drug, diagnostic or other use.

Call today for more information.

We are here to support your work in every way with our advanced product line and our staff's technical expertise. Call us toll free.

1-800-332-1042

In the U.S.
Genzyme Corporate Headquarters
75 Kneeland Street
Boston, Massachusetts 02111
Telephone (617) 451-1923

In the U.K. or Europe
Koch-Light Ltd.
37 Hollands Road
Haverhill, Suffolk CB9 8PU
(0440) 702436
Quick. Forget it.

The Sysmex™ CC-180 Hematology Analyzer

The benefits of having a Sysmex CC-180 semi-automated hematology analyzer are summed up in two simple statements.

**Quick.**
The CC-180 is quick indeed.
Dual apertures combined with dual volumetric manometers give you simultaneous counting of both WBC and RBC/Plt samples. Press one button, and your 8-parameter results arrive in a mere 27 seconds. Platelet counts are automatically determined from the RBC dilution without any additional steps or effort.
Start-up and shutdown are also quick; less than 5 minutes for each.

**Forget it.**
Forget the inconveniences of conventional semi-automated instruments. The Sysmex CC-180's microprocessor gives you attention-free performance. Up to 33 alert messages instantly appear on the CRT to flag abnormalities, while the memory stores the results of 100 patient samples.
The CC-180 has a quality control program and automatic calibration for Hct and Hgb. And, for totally worry free operation, the analyzer automatically performs recounts when detecting aperture clogs, background noise or test results outside of user-defined limits.
The CC-180 system is supported by American Scientific Products' extensive nationwide service network and includes a complete system of reagents and controls. For more information on the Sysmex System contact your local American S/P representative, or write: American Scientific Products, 1430 Waukegan Road, McGaw Park, IL 60085, Telephone 312/689-8410.

American Scientific Products